Kerri Fitzgerald

DocwireNews

A phase III trial presented at the ESMO Congress 2019 found that Lynparza&reg; (olaparib) resulted in longer delayed disease progression&nbsp;compared with hormonal agents <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/erleada-vs-xtandi-a-comparison-of-prostate-cancer-drugs/">Xtandi&reg; (enzalutamide)</a> and Zytiga&reg; (abiraterone acetate) in men with <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/high-throughput-screening-used-to-identify-promising-prostate-cancer-treatments/">metastatic prostate cancer</a>.The study compared the efficacy of the PARP inhibitor olaparib versus physician&rsquo;s choice of hormonal therapy (enzalutamide or abiraterone acetate) in two cohorts of men with metastatic castration-resistant prostate cancer. Cohort A included men with alterations in&nbsp;BRCA1,&nbsp;BRCA2,&nbsp;or&nbsp;ATM&nbsp;genes; cohort B included men with alterations in any of 12 other genes known to be involved in DNA repair.<h2>Improved disease progression with olaparib</h2>In Cohort A, median progression-free survival (PFS) was 7.39 months in those receiving olaparib compared with 3.55 months in those receiving hormonal treatment (hazard ratio [HR] = 0.34; P&lt;0.0001). In both cohorts, median PFS was 5.82 months with olaparib versus 3.52 months with hormonal treatment (HR=0.49; P&lt;0.0001).An interim analysis found that the median overall survival (OS) in Cohort A was 18.5 months with olaparib compared with 15.11 months with hormonal treatment (HR=0.64; P=0.0173). Median OS in both cohorts was 17.51 months with olaparib and 14.26 months with hormonal therapy (HR=0.67; P=0.0063).Adverse events (AEs) were more common in the olaparib group; however, the median treatment duration was longer with olaparib (7.4 months) than hormone treatment (3.9 months). The most common AEs in the olaparib group were anemia, nausea, decreased appetite, and fatigue. In the olaparib group, 16.4% of patients discontinued treatment due to AEs compared with 8.5% in the hormonal treatment cohort.&ldquo;To see such a significant effect on disease progression and other clinically relevant effects such as pain progression and objective response rate is a remarkable achievement in such heavily pre-treated patients with prostate cancer,&rdquo; said study author Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, in a press release. &ldquo;Prostate cancer has lagged behind all other common solid tumors in the use of molecularly targeted treatment, so it is very exciting that now we can personalize an individual&rsquo;s treatment based on specific genomic alterations in their cancer cells.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Lynparza® Delays Prostate Cancer Progression Compared With Xtandi® and Zytiga®

Oncology

A phase III trial presented at the ESMO Congress 2019 found that Lynparza® (olaparib) resulted in longer delayed disease progression compared with hormonal agents Xtandi® ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe